MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
This study is a double-blind, randomized study of MK0991 versus liposomal amphotericin B in
the empirical treatment of pediatric patients (ages 2 through 17 years) who have an absolute
neutrophil count (ANC) below 500/microliter and who have fever despite broad antibiotic
coverage. Such patients would be candidates for empirical therapy with an intravenous
anti-fungal agent.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Amphotericin B Caspofungin Liposomal amphotericin B